These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 2993418

  • 1. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA.
    J Immunol; 1985 Oct; 135(4):2865-75. PubMed ID: 2993418
    [Abstract] [Full Text] [Related]

  • 2. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
    Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA.
    J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
    [Abstract] [Full Text] [Related]

  • 3. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
    Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, Levitt D, Fefer A.
    Cancer Res; 1989 Jan 01; 49(1):235-40. PubMed ID: 2783243
    [Abstract] [Full Text] [Related]

  • 4. Systemic administration of interleukin-2 in humans.
    Lotze MT, Robb RJ, Sharrow SO, Frana LW, Rosenberg SA.
    J Biol Response Mod; 1984 Oct 01; 3(5):475-82. PubMed ID: 6334135
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J.
    Clin Cancer Res; 1996 Mar 01; 2(3):493-9. PubMed ID: 9816195
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J, Burns LJ.
    Biol Blood Marrow Transplant; 1997 Apr 01; 3(1):34-44. PubMed ID: 9209739
    [Abstract] [Full Text] [Related]

  • 12. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
    Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL.
    Cancer Res; 1988 Jul 01; 48(13):3875-81. PubMed ID: 3132324
    [Abstract] [Full Text] [Related]

  • 13. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
    Sano T, Saijo N, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Sakurai M, Takahashi H, Nakano H, Nakagawa K.
    Jpn J Cancer Res; 1988 Jan 01; 79(1):131-43. PubMed ID: 3128501
    [Abstract] [Full Text] [Related]

  • 14. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ.
    Cancer Res; 1988 Sep 01; 48(17):5007-10. PubMed ID: 3261630
    [Abstract] [Full Text] [Related]

  • 15. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr 01; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

  • 16. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
    Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS.
    Bone Marrow Transplant; 2003 Jul 01; 32(2):177-86. PubMed ID: 12838283
    [Abstract] [Full Text] [Related]

  • 17. Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.
    Yamaguchi S, Onji M, Kondoh H, Miyaoka H, Ohta Y.
    Clin Exp Immunol; 1988 Oct 01; 74(1):1-6. PubMed ID: 2975535
    [Abstract] [Full Text] [Related]

  • 18. In vivo administration of purified Jurkat-derived interleukin 2 in mice.
    Donohue JH, Lotze MT, Robb RJ, Rosenstein M, Braziel RM, Jaffe ES, Rosenberg SA.
    Cancer Res; 1984 Apr 01; 44(4):1380-6. PubMed ID: 6608405
    [Abstract] [Full Text] [Related]

  • 19. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y, Suzuki Y, Katakura R, Miyagi T, Yamaguchi T, Yoshimoto T, Ebina T.
    Clin Cancer Res; 1997 Apr 01; 3(4):633-43. PubMed ID: 9815731
    [Abstract] [Full Text] [Related]

  • 20. Toxicity of recombinant human interleukin-2 in rats following intravenous infusion.
    Matory YL, Chang AE, Lipford EH, Braziel R, Hyatt CL, McDonald HD, Rosenberg SA.
    J Biol Response Mod; 1985 Aug 01; 4(4):377-90. PubMed ID: 3875693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.